Glenmark Pharma’s arm gets tentative nod for Calcipotriene and Betamethasone Dipropionate Foam

09 May 2022 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval from the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%-0.064%, the generic version of Enstilar Foam, 0.005%-0.064%, of Leo Pharma AS.

According to IQVIA sales data for the 12 month period ending March 2022, the Enstilar Foam, 0.005%-0.064% market achieved annual sales of around $115.2 million.

Glenmark’s current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA’s pending approval with the U.S. FDA.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2011.65 18.95 (0.95%)
29-Jan-2026 14:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1592.85
Dr. Reddys Lab 1210.00
Cipla 1323.00
Zydus Lifesciences 890.10
Lupin 2129.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×